T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity
Mar 29, 2005 - 5:36:00 PM
Larche and colleagues investigated this pathway further by treating individuals who were allergic to cats with short synthetic peptides based on the major trigger for cat allergy and then measuring the clinical and immunological response to allergen. T
By PLoS Medicine, [RxPG] In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Asthma and allergy have become more frequent in all industrialized countries during recent decades, and there is much debate about exposure to pets in early life and later development of asthma and allergy. Some studies have suggested that keeping pets actually protects against later allergy - i.e., that early exposure may somehow modify an individual's immune system to tolerate specific antigens. Various attempts to modify abnormal immune responses to specific allergens, such as those to cat dander, have been made. Investigators have previously treated patients with related molecules, either peptides derived from the allergen itself, or much smaller peptides produced synthetically. Although therapy with peptides seems to reduce allergic responses, the mechanism of the response to treatment has not been clear; in particular, it is not clear exactly which cells are involved in modifying the immune response.
Larche and colleagues investigated this pathway further by treating individuals who were allergic to cats with short synthetic peptides based on the major trigger for cat allergy and then measuring the clinical and immunological response to allergen. They found that treatment with the peptides led to the production of a population of T cells that suppressed the proliferation of allergen-reactive T cells in vitro.
Publication:
Citation: Verhoef A, Alexander C, Kay AB, Larche M (2005) T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2(3): e78.
On the web:www.plosmedicine.org
Advertise in this space for $10 per month.
Contact us today.
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org
Feedback
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
